KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Tax Provisions (2023 - 2025)

Recursion Pharmaceuticals' Tax Provisions history spans 3 years, with the latest figure at $20000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 185.71% year-over-year to $20000.0; the TTM value through Dec 2025 reached -$135000.0, up 88.03%, while the annual FY2025 figure was -$136000.0, 87.93% up from the prior year.
  • Tax Provisions reached $20000.0 in Q4 2025 per RXRX's latest filing, up from $3000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $167000.0 in Q3 2024 to a low of -$4.1 million in Q4 2023.
  • Average Tax Provisions over 3 years is -$665625.0, with a median of -$77500.0 recorded in 2025.
  • The largest YoY upside for Tax Provisions was 185.71% in 2025 against a maximum downside of 98.2% in 2025.
  • A 3-year view of Tax Provisions shows it stood at -$4.1 million in 2023, then skyrocketed by 100.17% to $7000.0 in 2024, then skyrocketed by 185.71% to $20000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Tax Provisions are $20000.0 (Q4 2025), $3000.0 (Q3 2025), and -$158000.0 (Q1 2025).